Good morning!
If you thought PositiveID Corp. (PSID) had contrarian “potential” before, the combination of news and recent action makes it even more compelling!
The chart looks primed for a breakout move, the news is flowing and it’s still only $0.025! What more do you want in a Tuesday morning trade?
It may seem cold to trade the rising odds of a viral disaster, but when you refresh the PSID chart you’ll see the $0.03 forces we’re now dealing with:
Down here, every 1/2 cent that PSID swings has already put big percent on the day traders’ books -- and a fresh breakout may be on the way!
We’re awful close to what looks like a $0.025 base with the top and bottom trends coming in nice and smooth, so PSID technically needs to move soon.
What intrigues me, of course, is how PSID made that leap “all the way” to $0.038, which is now a tempting 55% beyond Friday’s action.
Turns out PSID has started shipping its virus diagnostic kits to the Pentagon testing field ahead of active deployment in Korea!
Biological threat detection is shaping up as a $2.6 BILLION market with another $3 billion or so overseas. PSID wants a piece of that! (Read more)
Clearly Uncle Sam does not want our best and brightest exposed to an actual flesh-eating plague without the kind of protection PSID can provide!
With Iraq going crazy again and the Russians rattling around Ukraine, theglobal risk needle is moving back to “yellow.”
Is it any wonder PSID just booked its first $3.5 million in revenue and is working on up to $7 million more in live contracts from people like NASA? (Read more)
Remember, vaccine stocks like Novovax and Inovio show the deep potential for a company like PSID that can point out who needs quarantine or a shot.
When the fear factor gets rolling and the big boys start stockpiling diagnostics, those charts start to shine -- PSID could do likewise!
And with PSID finally getting its gear into Pentagon lockers and breaking out into headlines, I can’t help feeling that we’re in for some thrills here.
Recent News:
Reviewing the $PSID January 2015 Shareholder Update
PositiveID Corp. (OTC: PSID) recently released a shareholder update on their website. The update breaks down key points of current operations and expected progress in their M-BAND and Firefly Dx product lines. The company has positioned their bio-threat detection and rapid medical testing molecular diagnostic systems very effectively in the high growth biosensor sector. The company’s innovative products are very well-protected in a legal sense; there are 20 patents (including patents pending) and rising.
The M-BAND was developed with $30 million in developmental funding from the U.S. Department of Homeland Security, meaning that the public sector is already placing large bets on the ingenuity of PositiveID Corp. The company feels that getting their foot in the door with the Department of Homeland Security, so to speak, could lead to strong positioning for next-generation bio-detection programs through the government moving forward. This is the company’s bio-threat detection product.
The company has been paid $2.5M by Boeing in a license and teaming agreement that gives Boeing exclusive manufacturing and distribution rights for the M-BAND in the U.S. PositiveID Corp. will be the exclusive provider of reagents and assays for the M-BAND to Boeing. This could develop nice revenue streams down the road. PositiveID Corp. is making large contracts in both the private and public sectors.
The company has been paid $2.5M by Boeing in a license and teaming agreement that gives Boeing exclusive manufacturing and distribution rights for the M-BAND in the U.S. PositiveID Corp. will be the exclusive provider of reagents and assays for the M-BAND to Boeing. This could develop nice revenue streams down the road. PositiveID Corp. is making large contracts in both the private and public sectors.
The company’s commercial diagnostics product is called Firefly Dx. This product was developed for the $27 billion dollar commercial diagnostics market. It is a rapid medical testing device that is highly effective, portable, and much faster than traditional diagnostic methods. The company has made agreements with entities such as NASA, ENSCO, and USSOCOM already. They are expecting Firefly Dx to create a significant pipeline for revenue in 2015/2016.
Additionally, in order to continue development of the Firefly Dx in a responsible way, PositiveID Corp. has entered a favorable $4 million financing deal with Dominion Capital, which has a “no-shorting” provision. This extra financing will allow the company to continue developing the FIrefly Dx and help to bring it to market.
The company booked its first revenues over the past year (2014) since it was founded. The company is on track to deliver $4-10 million in revenue in 2014 and 2015 combined, as per the update.
No comments:
Post a Comment